(Q39335010)

11 September 2017

title

Short-term safety and tolerability of double-dose salmeterol/fluticasone propionate in adult asthmatic patients (English)

1 reference

11 September 2017

0 references

Lars-Erik Adolfsson

1

1 reference

11 September 2017

Michael Lundgren

2

1 reference

11 September 2017

Bjorn Tilling

3

1 reference

11 September 2017

Sverker Jern

4

1 reference

11 September 2017

Christina Tyren

5

1 reference

11 September 2017

Alex Godwood

6

1 reference

11 September 2017

Dee Gor

7

1 reference

11 September 2017

publication date

1 January 2005

1 reference

Clinical Drug Investigation

11 September 2017

published in

1 reference

11 September 2017

volume

25

1 reference

11 September 2017

issue

4

1 reference

11 September 2017

page(s)

231-241

1 reference

Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?

11 September 2017

cites work

1 reference

12 December 2020

A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma

1 reference

12 December 2020

The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation

1 reference

12 December 2020

Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group

1 reference

12 December 2020

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

12 December 2020

Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring

1 reference

12 December 2020

British guideline on the management of asthma

1 reference

12 December 2020

A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group

1 reference

12 December 2020

High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group

1 reference

12 December 2020

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

12 December 2020

Systemic effects of salbutamol and salmeterol in patients with asthma

1 reference

12 December 2020

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1 reference

12 December 2020

Salmeterol 100 microg: an analysis of its tolerability in single- and chronic-dose studies

1 reference

12 December 2020

Dose-response study with high-dose inhaled salmeterol in healthy subjects

1 reference

12 December 2020

Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr.

1 reference

12 December 2020

Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease

1 reference

12 December 2020

Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.

1 reference

12 December 2020

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

12 December 2020

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

12 December 2020

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

12 December 2020

Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

1 reference

12 December 2020

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

12 December 2020

Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler

1 reference

12 December 2020

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers

1 reference

12 December 2020

A comparison of the efficacy and safety of inhaled corticosteroids in asthma

1 reference

12 December 2020

Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial

1 reference

12 December 2020

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

1 reference

12 December 2020

10.2165/00044011-200525040-00002

Identifiers

DOI

1 reference

11 September 2017

1 reference